← Retour au Screener

Sector: Santé
Open in Terminal → CRVSLive chart · Key metrics · News · Smart money

Corvus Pharmaceuticals

CRVS Small Cap

Healthcare · Biotechnology

Mis à jour: Jun 18, 2026, 22:21 UTC

10,39 €
-0.75% aujourd'hui
52W: 3,10 € – 23,52 €
52W Low: 3,10 € Position: 35.7% 52W High: 23,52 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
874 M €
Capitalisation boursière
Croissance du CA
Croissance du CA sur un an
Marge bénéficiaire
Marge nette
ROE
-30.46%
Rentabilité des capitaux propres
Beta
0.84
Sensibilité au marché
Positions vendeuses
23.42%
% du flottant vendu à découvert
Volume moyen
1,482,296
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Achat Fort
6 analysts
Avg. Price Target
29,09 €
+179.88% upside
Target Range
23,56 € – 36,65 €

About the Company

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 37 Exchange: NGM

Corvus Pharmaceuticals en bref

Corvus Pharmaceuticals (CRVS) is currently trading at 10,39 € with a market capitalization of 874 M €. The 52-week range spans from 3,10 € to 23,52 €; the current price is 55.8% below the yearly high.

💰 Dividende

Corvus Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

6 analystes évaluent Corvus Pharmaceuticals (CRVS) au consensus : Achat Fort. L'objectif de cours moyen est de 29,09 €, soit un potentiel de +179.88% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 23,56 € à 36,65 €.

Corvus Pharmaceuticals : la thèse d'investissement en détail

Corvus Pharmaceuticals (CRVS) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Strong Buy with an average price target implying roughly 179.88% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Short interest sits at 23.42% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

  • The analyst consensus price target implies 179.88% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts
  • Consensus des analystes : Strong Buy
  • Bilan solide avec faible endettement (D/E 0.35)
Points faibles
  • Positions vendeuses élevées (23.42%)
  • Free cash flow négatif

Aperçu technique

MM 50 jours
12,15 €
-14.44% vs. cours
MM 200 jours
10,31 €
+0.85% vs. cours
Sous le plus haut 52s
−55.8%
23,52 €
Au-dessus du plus bas 52s
+235.5%
3,10 €

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

Risque de marché (Bêta)
0.84 · Proche du marché
Évolue moins que le marché global
Positions vendeuses
23.42% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
0.35 · Faible
Dette totale / capitaux propres

The data points to relatively defensive market behavior, elevated short interest (23.42%).

Trading Data

50-Day MA: 12,15 €
200-Day MA: 10,31 €
Volume: 1,625,698
Avg. Volume: 1,482,296
Short Ratio: 9.62
P/B Ratio: 4.16x
Debt/Equity: 0.35x
Free Cash Flow: -19 698 697 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Corvus Pharmaceuticals?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut